Warning Letter — Graceful Touch, LLC
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to Graceful Touch, LLC following an evaluation of the company's regulatory compliance status.
Graceful Touch, LLC, and regulatory professionals responsible for monitoring compliance with CDER requirements regarding product claims and marketing.
The issuance of a Warning Letter by CDER typically indicates significant deviations from the Federal Food, Drug, and Cosmetic Act. For companies in this space, this represents a high risk of escalated enforcement action if corrective measures regarding product classification or labeling are not documented and implemented.
Regulatory and compliance teams should immediately audit all external-facing materials to ensure that product claims do not cross the threshold into unapproved drug territory. Quality units should review internal protocols for vetting marketing language against established regulatory definitions.
FDA Warning Letter issued to: Graceful Touch, LLC. 10/01/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/graceful-touch-llc-735272-10012026
Open in openFDA / FDA.gov